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Abstract 
Congenital Disorders of Glycosylation (CDG) are a rapidly expanding group of rare genetic defects in 
glycosylation. In a novel CDG subgroup of Vacuolar-ATPase assembly defects various degrees of 
hepatic injury have been described, including end stage liver disease. However, the CDG diagnostic 
workflow can be complex as liver disease per se may be associated with  abnormal glycosylation. 
Therefore, we collected serum samples of patients with a wide range of liver pathology to study the 
performance and yield of two CDG screening methods. Our aim was to  identify glycosylation 
patterns that could help to differentiate between primary and secondary glycosylation defects in 
liver disease.   
To this end, we analyzed serum samples  of 1042 adult liver disease patients. This cohort consisted of 
567 liver transplant candidates and 475 chronic liver disease patients. Our workflow consisted of 
screening for abnormal glycosylation by transferrin isoelectric focusing (tIEF), followed by in-depth 
analysis of the abnormal samples with quadruple time-of-flight mass spectrometry (QTOF-MS). 
Screening with tIEF resulted in identification of 247 (26%) abnormal samples. QTOF-MS analysis of 
110 of those did not reveal glycosylation abnormalities comparable with those seen in V-ATPase 
assembly factor deficiencies. However, two patients presented with isolated sialylation deficiency. 
Fucosylation was significantly increased in liver transplant candidates compared to healthy controls 
and patients with chronic liver disease.  
In conclusion, a significant percentage of patients with liver disease presented with abnormal CDG 
screening results, however, not indicative for a V-ATPase assembly factor defect.  Advanced 
glycoanalytical techniques assist in the dissection of secondary and primary glycosylation defects.   
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Take home message 
Secondary glycosylation defects are common in liver disease and advanced glycoanalytics are needed 
to differentiate these from primary glycosylation defects such as the V-ATPase assembly factor 
deficiencies.  
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1. Introduction 
Congenital disorders of glycosylation (CDG) are a group of inborn errors of metabolism characterized 
by abnormal glycosylation. Most CDG share a multisystem phenotype with dysmorphic features, 
failure to thrive and neurological symptoms.(Peanne et al 2017) Involvement of the liver is frequent 
in CDG but usually not the dominant feature. (Marques-da-Silva et al 2017)  
In recent years, a novel subgroup of CDG patients has emerged that presents predominantly 
with a hepatic phenotype. (Jansen et al 2016; Jansen et al 2016; Jansen et al 2016; Rujano et al 2017; 
Cannata Serio et al 2020) Pathological variants in this group are in genes that code for assembly 
factors of the vacuolar -ATPase (V-ATPase), the proton pump for intracellular acidification. The 
glycosylation pattern resembles a type 2 CDG with loss of sialic acid and galactose. The hepatic 
clinical spectrum ranges from mildly elevated serum transaminases and steatosis, resembling non-
alcoholic fatty liver disease, to cirrhosis and end-stage liver disease warranting liver transplantation 
(LTx).  
Liver cirrhosis develops as a response to chronic liver injury. The central pathological event in 
cirrhosis is deposition of extracellular matrix increasing hepatic flow resistance with ensuing 
hepatocyte dysfunction.(Tsochatzis et al 2014) Patients with cirrhosis have a high risk of 
decompensation of their liver disease. It can develop in end-stage liver disease (ESLD), necessitating 
(LTx) 
Abnormal glycosylation is a known phenomenon in chronic liver disease and can be used to 
discriminate between different fibrosis stages and cirrhosis and provides an interesting and non-
invasive alternative for liver biopsy.(Callewaert et al 2004). Abnormal glycan structures of liver-
derived proteins such as transferrin (TF) and haptoglobin have been described in alcoholic liver 
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disease, non-alcoholic steatohepatitis and primary sclerosing cholangitis.(Blomme et al 2009; Clarke 
et al 2017; Culver et al 2018) These abnormalities include hyperfucosylation due to increased 
fucosyltransferase activity and hyposialylation as a result of lower sialyltransferase activity.  
Traditionally, new CDG patients are identified through isoelectric focusing of TF 
(tIEF).(Francisco et al 2019) TF possesses two biantennary glycans at amino acids Asn432 and Asn630, 
both negatively charged because of the terminal sialic acids.(Guillard et al 2011) tIEF uses loss of 
these sialic acids to separate the various isoforms. A disadvantage of tIEF is that it only provides 
information on desialylation and not for example on hypogalactosylation and fucosylation. The use of 
quadruple time-of-flight mass-spectrometry (QTOF-MS) may overcome this disadvantage by 
providing in-depth high resolution information on the glycans attached to TF.(van Scherpenzeel et al 
2015)  
The primary aim of this study was to identify glycosylation patterns that could help to 
differentiate between primary and secondary glycosylation defects in liver disease within a cohort of 
adult patients with end-stage liver disease. As a secondary aim, we studied to what extent liver 
disease  affects CDG screening. 
 
2. Materials and methods 
2.1 Selection of liver disease patients, sample selection and ethical considerations 
We collected 1042 samples from patients with an established chronic liver disease  from four Dutch 
tertiary referral hospitals. (Figure 2) Samples were collected in the period 1993 to 2013. We 
specifically targeted ESLD patients who were evaluated and waitlisted for LTx. These samples were 
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provided by Erasmus MC in Rotterdam (n= 264), LUMC in Leiden (n=142) and UMCG in Groningen 
(n=155). All samples were drawn and aliquoted preceding LTx. 
Chronic liver disease samples (n=410), without ESLD, were provided by the Radboudumc in 
Nijmegen and by the LUMC (n=65, all with a diagnosis of auto-immune hepatitis). These patients 
were seen at the outpatient clinic for diagnosis and treatment of a range of liver diseases. Patients 
with viral hepatitis (infectious hepatitis B, C or E) were excluded from analysis as we hypothesized 
that the presence of underlying CDG would be unlikely in this patient population. Samples from 
healthy controls (n=40) were obtained from the local bloodbank. All samples were stored at −80 °C 
till analysis.  
Material was collected in agreement with the Dutch code of conduct for responsible use of 
human tissue (Dutch Federation of Biomedical Scientific Societies, www.federa.org). All experiments 
were performed in accordance with the guidelines and regulations of the Ethics Committee of the 
Radboudumc. Approval was documented in case file 2018-5012.  
2.2 Study design and workflow  
We first performed tIEF of the collected samples to identify global N-glycosylation defects with 
hyposialylation. Sixty-one samples were excluded prior to tIEF: 24 samples because they were drawn 
after liver transplantation, 21 were of very poor quality and unsuitable for further workup, 5 samples 
were wrongly allocated, 10 patients were <18 years of age at time of sampling and one sample was 
from a patient with an established diagnosis of CDG.  
 We defined abnormal TF sialylation as an increased percentage of hyposialylated TF isoforms 
compared with the main isoform, tetrasialo TF. Control ranges were used from the clinical diagnostic 
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protocol, derived by tIEF of 59 healthy control samples: asialoTF 0-3.2%; monosialoTF 0-5.0%; 
disialoTF 3.3-7.6%; trisialoTF 4.9-10.6%; pentasialoTF 18.7-31.5%.  
If applicable, we designated the profile type 1 or type 2 CDG based on international 
consensus. Type 1 CDG has increased asialo- and disialo TF isoforms, indicating loss of 1 or 2 glycans. 
Type 2 CDG has hyposialylation for all TF isoforms.(Lefeber et al 2011) 
Abnormal tIEF samples were selected for further work-up with QTOF-MS. Quality criteria for 
inclusion of the sample included an abundance of >50.000 amu of the intact TF glycoprotein (79556 
amu). We selected peaks corresponding to a known TF isoform with an abundance of >1000. The 
relative abundance of these peaks was calculated based on their percentage relative to total 
abundance. Figure 1 shows a typical tIEF and QTOF-MS pattern and depicts the nomenclature of the 
glycosylation isoforms used throughout this manuscript. 
2.3 Sample preparation for N-glycan analysis 
Transferrin isoelectric focusing 
All samples were analyzed with tIEF to determine abnormal sialylation of TF. tIEF was performed as 
described before. (Guillard et al 2011) Briefly, serum or plasma samples were incubated with iron 
and applied to a 5-7 pH gradient gel for electrophoresis. After completion, gels were incubated with 
2.5 µl/cm2 anti-TF antibody (Dako #A0061, Carpinteria, CA USA) and visualized with Coomassie blue. 
Data analysis was performed with Image Quant Software (Totallab, Newcastle upon Tyne, UK) 
TF polymorphisms were recognized by doubled bands for all isoforms. For confirmation, 
neuraminidase treatment was applied on samples with ambiguous isoelectric patterns. (Guillard et al 
2011)  
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Nano liquid chromatography-chip (C8)- quadruple time of flight mass spectrometry (QTOF-MS)  
Mass spectrometry analysis was performed as described before.(van Scherpenzeel et al 2015) First, 
beads were loaded with anti-TF antibody (Dako #A0061, Carpinteria, CA USA) and stored in 20% 
ethanol. Prior to usage, beads were washed 4 times with a Tris-HCl (pH 7) solution. Next, 100 µl of a 
1:10 plasma sample dilution in 0.9% sodiumchloride was mixed with beads and incubated for 20 
minutes under continuous shaking at 3000 rpm/min. Subsequently beads were washed four times 
with Tris-HCl (pH 7) solution. For elution, 1 µl of Tris-HCl pH 9 solution was added to the sample 
followed by 50 µl elutionbuffer (0.1M Glycine-HCl pH 2.7). After spinning and verification of neutral 
pH, 2µl sample was injected into the microfluidic 6540 HPLC-chip-QTOF instrument (Agilent 
Technologies, Santa Clara, CA, USA). For data analysis of QTOF-MS profiles Agilent Mass Hunter 
Qualitative Analysis software (v. B.04.00) was used.  
2.4 Statistical analysis 
For statistical analysis SPSS Statistics v. 22 (IBM Corporation, Armonk, NY, USA) was used. Due to 
non-linearity of our data we used the non-parametric Kruskall-Wallis test for comparisons of more 
than two groups and the Mann-Whitney U test when there were two groups. P-values were adjusted 
for multiple testing with the Bonferroni method.  
 
3. Results 
A total of 1042 samples were collected, 567 samples of LTx candidates and 475 samples of patients 
with CLD. Figure 2 shows a flowchart of the study design. We included 981 samples for further N-
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glycan analysis with tIEF. After tIEF, 744 samples including 20 samples with a confirmed 
polymorhpisms were excluded based on a normal profile  
Subsequently, QTOF-MS was performed on 247 samples and 40 healthy controls. After QTOF-
MS analysis, 125 samples were excluded because the main peak (at 79556 amu) was of insufficient 
abundance, 10 samples were excluded because of an abnormal glycation profile and 3 because of a 
TF polymorphism (of which 2 were not identified with tIEF and one was a healthy control). In total, 
110 patient samples and 39 healthy control samples were of sufficient quality for interpretation of 
the glycosylation profile. Table 1 shows patient characteristics for the selected samples. 
Supplementary table 1 shows tIEF and QTOF-MS results for all samples with an abnormal tIEF profile. 
3.1 tIEF screening of 961 samples of liver disease patients shows mild glycosylation abnormalities 
Out of 961 samples we analyzed using tIEF, 247 samples (26%) had hyposialylation compared to our 
controls. Of these samples, 175 (70%) had a solitary increased percentage of the trisialoTF isoform, 
42 (17%) had an elevated percentage of monosialoTF isoform and 4 (2%) had an elevated percentage 
of the disialoTF isoform. Mixed combinations of elevated isoforms occurred in 26 (11%) samples. 
(Figure 3a) None of the samples had increased percentages of all isoforms. One sample had slightly 
increased percentages of the asialo and the disialoTF isoform, and did not reach the values to be 
suggestive for type 1 CDG. The mixed profiles can be compatible with a CDG type 2 profile, however, 
in most samples the increase in percentage is subtle (Figure 3b). 
3.2 QTOF-MS analysis of preselected liver disease patients did not identify profiles compatible with 
V-ATPase assembly factor defects. 
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Of the 110 high quality QTOF-MS profiles, none had a distinguishable type 1 CDG pattern. The peak 
associated with non-glycosylated TF (peak 75140) was only present in one LTx patient with 
progressive familial intrahepatic cholestasis syndrome (1.2% of total glycan abundance), one CLD 
patient with auto-immune hepatitis (1.1%) and three HC (all <1% total glycan abundance). Both 
patients had a normal percentage of asialoTF in tIEF screening and the six patients with an elevated 
asialoTF fraction with tIEF analysis did not have a detectable peak with mass 75140, corresponding to 
non-glycosylated transferrin. Peak 77350, which corresponds to loss of one glycan, was present in all 
but five samples and was not significantly different among the groups (data not shown). We did not 
identify samples that showed typical glycan structural abnormalities that are seen in type 2 CDG 
profiles and did not identify a pattern compatible with a V-ATPase assembly factor deficiency.  
We identified two samples (2/110 = 1.8%) with clearly elevated trisialo TF isoform 
abundance. The first patient in the CLD group was a female, age 55 at sampling, who was seen at the 
outpatient clinic for hepatic steatosis. Her profile showed an elevated trisialo TF isoform of 15.0%, 
(median for the CLD group is 2.0%) and presence of an additional isoform (mass 78976, 
corresponding with loss of 2 sialic acids). There were no signs of other glycosylation abnormalities. 
The second patient was a male liver transplant recipient diagnosed with alpha-1 anti-trypsin 
deficiency. At age of sampling he was 28 years old. His QTOF-MS profile showed an increase in the 
trisialo TF isoform of 12,4% (median for the LTx group is 1.9%) and also an increased loss of 2 sialic 
acids (mass 78976). For both patients, we could not detect transferrin glycoforms with missing 
galactose residues, as for example seen in the V-ATPase assembly defects.  
3.3 tIEF but not QTOF-MS shows that loss of one sialic acid is more frequent and more severe in LTx 
candidates compared to CLD patients and HC 
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To see what the effect is of liver disease on desialylation we compared the tIEF screening results 
between LTx and CLD samples. Table 2 shows the medians for all isoforms. The prevalence of several 
isoforms were statistically significantly different between these groups, but medians where within 
the normal range. Only the LTx group had a median of the trisialo TF isoform above the upper limit of 
normal and significantly higher than in the chronic liver disease group (11.8% vs 10.4%, p <0.001). An 
abnormal tIEF pattern was more frequently seen in LTx candidates compared to CLD patients 
(175/511=34% vs. 72/450=16%, Chi square p-value =0.000).  
 Next, we aimed to gain more insight in desialylation with QTOF-MS. QTOF-MS provides  
additional detail on glycan composition. To investigate desialylation we used the combined 
abundance of the trisialo and the fucosylated trisialo TF isoform. Comparison of these combined 
peaks among the three groups only showed a slight statistically significant difference between the 
LTx and CLD groups (Supp. Table 2). However, because of the broad standard deviations we conclude 
that overall desialylation is not different between LTx candidates, CLD patients and healthy controls. 
In conclusion, based on these data, desialylation is more prominent in LTx candidates when 
measured with tIEF, but this data is not reproduced with QTOF-MS. 
3.4 Hyperfucosylation more pronounced in end-stage liver disease than in chronic liver disease 
Hyperfucosylation of liver derived proteins is a known phenomenon in a variety of liver diseases. 
Therefore, we calculated the fucosylation ratio for the trisialo and pentasialo TF isoforms. (Figure 4 
and Supp. Table 2). Fucosylation of the tetrasialo TF isoform was not reliably detectable because of 
overlap with other nearby peaks. Figure 4 shows that the ratios are higher for the LTx samples 
compared to the HC and the CLD samples (p<0.0001 for both). These data indicate that 
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hyperfucosylation of TF is more pronounced in end-stage liver disease compared to chronic liver 
disease and healthy controls.  
 
4. Discussion  
In our retrospective analysis of a cohort of 1042 liver disease patients we found a significant 
percentage of patients with altered CDG screening results by serum transferrin isoelectricfocusing. 
However, we did not find clear evidence for the presence of a CDG due to V-ATPase assembly factor 
defects.  We found that hyperfucosylation is more pronounced in LTx patients compared to those 
with milder liver disease and healthy controls, thereby showing that high-resolution mass 
spectrometry aids the discrimination between secondary and primary glycosylation abnormalities in 
CDG screening.  
4.1 Screening for possible primary glycosylation defects 
Initial  screening with tIEF resulted in identification of 247 (26%) , mostly mild, abnormal patterns. 
We did not identify a typical CDG type 1 pattern, which we anticipated, as to date there are no 
known type 1 CDG associated with  a mild hepatic phenotype.(Peanne et al 2017) The majority of 
samples had an increase in the trisialo TF isoform. None had an increase of all isoforms, a feature of 
most type 2 CDG. However, based on these tIEF results we could not rule out a V-ATPase assembly 
factor deficiency as mild abnormalities have been described. QTOF-MS analysis did not confirm 
desialylation as seen in tIEF and did not show patterns compatible with type 1 CDG or V-ATPase 
assembly factor deficiencies. Similarly,  no samples with loss of galactose were observed. Therefore 
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we conclude that our analysis did not  identify novel  patients with a V-ATPase assembly factor 
defect. 
A possible reason for this might  be that prevalence is too low for detection within our 
cohort. The exact prevalence of the whole group of CDG is unknown, but is estimated at 0.1 – 0.5 / 
100.000 in Europe. This number is based on recent data from the European CDG network that 
estimated that there is a total number of 2500 recognized CDG patients in Europe. (Peanne et al 
2017) However, these observations are based on patients with a multisystem phenotype. The  
discovery of the V-ATPase-CDG subgroup with a  very mild hepatic phenotype could indicate that the 
prevalence is much higher. We speculated that this subgroup would be enriched in a population that 
covers the full spectrum of liver disease severity, but no cases were detected.  
Another reason might be that glycosylation defects of CDG patients who survive into 
adulthood can become milder, or even normalize, over time. (Westphal et al 2001; Ng et al 2013; 
Wolthuis et al 2014). Spontaneous normalization of the glycosylation profile has not yet been 
investigated for V-ATPase-CDG. However, spontaneous normalization of serum transaminases has 
been described with this condition. (Jansen et al 2016) 
We identified two patients with an abnormally high percentage of the isoform with loss of 
one sialic acid. The reason for this abnormal pattern remains unknown. Glycosylation defects in 
SLC35A1-CDG (OMIM 603585), a defect in the CMP-sialic acid transporter, show pure desialylation 
effects (Martinez-Duncker et al 2005; van Scherpenzeel et al 2015). However, the phenotype of 
SLC35A1-CDG is mostly neurological with dysmorphic features, not hepatic. 
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Also, the presence of bacterial sialidase in serum can lead to hyposialylation of TF. This has 
been described for Streptococcus pneumoniae- associated hemolytic ureum syndrome.(Scobell et al 
2019). However, hemolytic uremic syndrome is primarily a disease of infancy and early childhood and 
the incidence in the adult population is extremely low.  
Another option is that these patients have an as yet unrecognized  type of CDG. Our study 
design did not allow us to further investigate this as we did not have access to fresh plasma, 
fibroblasts or parental DNA to perform adequate genetic analyses and functional studies. 
 
4.2 Glycosylation defects in liver disease 
Desialylation has been mostly studied in the context of alcoholic liver disease. Indeed, the 
Carbohydrate Deficient Transferrin (CDT) test to identify chronic alcohol intake is based on 
desialylation of transferrin. Analysis of CDT in abstaining patients with various degrees of liver 
disease shows a correlation of high CDT percentages with the Child-Pugh score.(DiMartini et al 2001)  
 The pathophysiological mechanism behind alcohol-induced hypoglycosylation is not fully 
elucidated. Some studies suggest a primary ER defect (Cottalasso et al 2002; Flahaut et al 2003). 
Other studies suggest an effect on the Golgi apparatus.(Ghosh et al 1995; Gong et al 2007). One 
study investigated  gene expression of glycosylation genes in NASH, but found mixed results with 
upregulation of ST6GAL2 and downregulation of ST6GAL1.(Clarke et al 2017)  
 Hyperfucosylation of liver derived proteins has been most extensively studied in 
hepatocellular carcinoma patients. (Pompach et al 2013; Huang et al 2017; Zhang et al 2017; Verhelst 
et al 2020) Indeed, fucosylated alpha-fetoprotein is an established disease marker for HCC in the 
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setting of cirrhosis.(Sato et al 1993) Here we show that fucosylation of transferrin is elevated in 
samples from LTx candidates compared to CLD patients and healthy controls.  
 Hyperfucosylation of transferrin was shown to be the cause of chromatographic 
abnormalities in CDT testing, or so-called “di-tri-bridging” (i.e. poor resolution of disialoTF from 
trisialoTF).(Landberg et al 2012) Di-tri-bridging is associated with liver disease and is more frequent in 
cirrhosis than in non-cirrhotics.(Stewart et al 2017) 
Somewhat older data exists on fucosylation of haptoglobin in liver disease and shows 
hyperfucosylation in patients with alcoholic liver disease and primary biliary cholangitis.(Mann et al 
1994) A more recent paper showed increased hyperfucosylated glycans on haptoglobin in HCC as 
well as in cirrhosis. (Zhu et al 2014)  
Previous work on serum glycan analysis in liver cirrhosis identified increased 
hypogalactosylation and increased modification of the serum N-glycome with a bisecting N-
acetylglucosamine.(Callewaert et al 2004) Log ratios of different glycans could with good sensitivity 
and specificity discriminate between early fibrosis and cirrhosis. A follow-up study showed that 
undergalactosylation was due to the IgG-derived glycan fraction.(Vanderschaeghe et al 2009) This is 
in line with our data that did not show undergalactosylation in any sample. Also, no glycans were 
observed within our cohort with a bisecting N-acetylglucosamine. This might be explained by protein 
specific glycosylation.  
4.3 Strengths and limitations   
One strength of our study was that we included a wide range of  liver disease patients for analysis. 
We took care to include patients with mild liver disease but also those with advanced chronic liver 
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disease in need for LTx. Our efforts led to the establishment of a large sample size  of over 1000 liver 
disease patients which adds to the robustness of the study. Additionally, we were able to screen 
these samples with high resolution mass spectrometry that provided in depth analysis of the intact 
transferrin glycoprotein, including fucosylation, loss of galactose and the absence of complete 
glycans. 
 A limitation of our study is because of its retrospective character. We had access to collected 
serum samples but were not in possession of fresh plasma or fibroblasts of patients to perform 
whole-exome sequencing, run a CDG-panel, or perform functional studies. We detected  two patients 
with an increased trisialoTF isoform. Although the cause for this elevation is unknown we believe 
that the  QTOF-MS analysis ruled  out abnormal glycosylation due to a defect in V-ATPase-CDG. 
However, we cannot completely exclude  another, possibly novel, CDG.  
 Another limitation of our study is the high percentage of exclusion of samples resulting from  
low abundance of serum TF in the samples. A possible explanation could be that low serum TF is 
associated with cirrhosis.(Bruns et al 2017; Viveiros et al 2018). Additionally, the effect of long term 
storage on stability of TF  is  unknown. 
4.4 Recommendations 
Differentiating primary from secondary glycosylation defects in patients with liver dysfunction can be 
challenging. Previously analysis of total plasma N-glycans suggested that hyperfucosylation was 
increased in a single liver disease patient but not in primary CDG.(Guillard et al 2011) This study 
expands these findings to a large patient group and thus transferrin hyperfucosylation pattern could 
guide clinicians in decision making. 
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Our current research exposes caveats in tIEF as a primary diagnostic step. We show that 26% 
of tiEF samples were abnormal, but these samples did not show a clear type 2 CDG pattern upon  
QTOF-MS analysis. An important message is that  tIEF screening can be false positive because of liver 
dysfunction. 
We suggest caution when interpreting tIEF result in patients with a suspected CDG and liver 
disease and recommend to maintain a low-threshold to use advanced glycoanalytic methods, 
preferably in an expertise center. A clear hyperfucosylated pattern is more suggestive for a 
secondary cause and loss of galactose more suggestive for a primary glycosylation defect. When only 
sialylation is decreased we suggest a repeat sample to rule out the involvement of exogeneous 
sialidase and a critical review of the phenotype to rule out a CDG with known hyposialylation. 
 
5. Conclusion 
Our screening study did not identify V-ATPase assembly factor defects in a cohort of severe liver 
disease, but we show that end-stage liver disease is associated with hyperfucosylation of transferrin. 
We confirm that regular CDG screening with tIEF can be complicated by liver disease, itself is 
associated with mildly abnormal tIEF profiles  
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Tables 
Table 1. Patient characteristics  
 tIEF selected samples (n=961) QTOF-MS selected samples (n=149) 
 LTx (n=511) 
CLD 
(n=450) 
LTx 
(n=76) 
CLD 
(n=34) 
HC 
(n=39) 
Mean age (years)  48.5 (SD 12.2) 
50.0 
(SD 15.5) 
52.6 
(SD 12.0) 
51.8 
(SD 13.2) 
47.1 
(SD 14.2) 
Male sex 283 (55.4%) 211 (46.9%) 50 (65.8%) 15 (44.1%) 21 (53.8%) 
Etiology      
Acute liver 
failure 
38 (7.4%) 2 (0.4%) 1 (1.3%) 0 n.a. 
Alcohol liver 
disease 
121 (23.7%) 20 (4.4%) 35 (46.1%) 6 (17.6%) n.a. 
Auto-
immune 
hepatitis 
39 (7.6%) 152 (33.8%) 3 (3.9%) 15 (44.1%) n.a. 
Cholestatic 
liver disease 
157 (30.7%) 42 (9.3%) 11 (14.5%) 0 n.a. 
Cryptogenic 
cirrhosis 
54 (10.6%) 20 (4.4%) 10 (13.2%) 1 (2.9%) n.a. 
Metabolic 
disease 
26 (5.1%) 7 (1.6%) 7 (9.2%) 0 n.a. 
NASH 10 (2.0%) 36 (8.0%) 0 3 (8.8%) n.a. 
Other  61 (11.9%) 36 (8.0%) 8 (10.5%) 2 (5.9%) n.a. 
Unknown 5 (1.0%) 5 (1.1%) 1 (1.3%) 0 n.a. 
Gilbert - 25 (5.6%) 0 2 (5.9%) n.a. 
Viral 
hepatitis - 
94 (20.9%) 0 5 (14.7%) n.a. 
DILI - 11 (2.4%) 0 0 n.a. 
LTx = Liver transplant recipient, CLD = Chronic liver disease, NASH = non-alcoholic steatohepatitis, 
DILI = drug induced liver injury. HC = healthy controls, SD= standard deviation, n.a. = not applicable 
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Table 2. medians of the different tiEF TF isoforms 
 Abnormal samples (n=247)  
CLD (n=72) LTx (n=175) MWU 
TF 
Isoform Range (%) Median (%) SD Median (%) SD p-value 
Asialo 0.0-3.2 0.94 1.02 1.24 0.79 0.001 
Mono 0.0-5.0 4.84 2.52 2.02 1.74 0.000 
Di 3.3-7.6 5.25 1.21 5.27 1.39 0.588 
Tri 4.9-10.6 10.40 3.07 11.84 2.25 <0.001 
Tetra 47.3 – 62.7 52.63 6.71 52.67 5.72 0.476 
Penta 18.7 - 31.5 20.78 3.94 19.95 3.44 0.038 
TF=Transferrin, CLD=chronic liver disease, LTx=liver transplantation, MWU: Mann Whitney U test, 
SD=standard deviation 
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Figure legends 
Figure 1. Overview of a normal tIEF and QTOF-MS profile. A. Typical tIEF pattern. The most 
abundant fraction correlates with the intact TF glycoprotein. B Typical QTOF-MS profile of intact TF 
with two attached glycans. Shown are the most commonly encountered glycans. The green 
horizontal bar corresponds with the amino acid backbone. The peak at 79556 amu correlates with 
the intact TF glycoprotein. The legend for the monosaccharides is: blue square: N-acetylglucosamine, 
red triangle: fucose, green circle: mannose, yellow circle: galactose, purple diamond: sialic acid. 
Figure 2. Flowchart of the study design.  
Figure 3. Abnormal tIEF result. A. Waffle chart that shows the distribution of the abnormal tIEF 
samples. B. Individual medians for the abnormal samples per TF isoform. The dotted line represents 
upper limit of normal based on internal standards. 
Figure 4. Boxplots of the fucosylation ratio of the tri- and pentasialo QTOF-MS isoforms. The left 
graph shows the fucosylation ratio of trisialotransferrin, or peak 79266. The right graph shows the 
fucosylation ratio of pentasialotransferrin, or peak 80211. We used a Kruskal-Wallis test for 
calculation of p-values. HC=healthy controls, CLD=chronic liver disease, LTx=liver transplantation 
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LTx recipients:
EMC: 264 samples
UMCG: 155 samples
LUMC: 148 samples
Chronic liver disease:
RUNMC: 410 samples
LUMC: 65 samples
total samples
n= 1042
tIEF samples
n=981
excluded based on
sample drawn post LTx n=24
poor sample quality n=21
wrong sample n=5
underage n=10
known CDG-patient n=1
excluded based on 
polymorphism n=20
normal tIEF n=714
abnormal tIEF
n=247
selected for 
QTOF-MS
n=287
high quality QTOF-MS 
profiles
n=149
excluded after QTOF-MS 
based on
poor sample quality n=123
abnormal glycation profile 
n=10
indeterminable profile n=2
polymorphism n=3 
healthy controls
n=40
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